Patent intelligence · US
US 7972793
Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
Patent details — US 7972793
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 5, 2011
- Expiration
- Jun 30, 2031
- Applicant
- SureGene LLC
- Claims
- 8
- CPC classes
- A61K, A61K31/00, A61K31/496, A61K31/519
Quick answer
US 7972793 (Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype) is held by SureGene LLC. Status: granted. Granted Jul 5, 2011. Expires Jun 30, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SureGene LLC
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/00, A61K31/496, A61K31/519, A61K31/5415, A61K31/55
More from SureGene LLC
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 7972793?
US 7972793 (Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype) is held by SureGene LLC. Status: granted. Granted Jul 5, 2011. Expires Jun 30, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7972793?
SureGene LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 7972793 expire?
Our index shows an expiration date of Jun 30, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.